CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Medicure Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Medicure Inc
1250 Waverley Street
Phone: (204) 487-7412p:204 487-7412 WINNIPEG, MB  R3T 6C6  Canada Ticker: MPHMPH
Business Summary
Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company's United States subsidiary, Medicure Pharma Inc. It also operates Marley Drug Inc. (Marley Drug), a pharmacy subsidiary servicing all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving access to medication for all Americans together with exceptional customer service and free home delivery. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome. It also develops pyridoxal 5'-phosphate analogues (P5P Analogues), the processes for their preparation, compositions containing P5P Analogues.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202412/31/2023YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations
5912 Drug stores and proprietary stores
5999 Miscellaneous retail stores, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer Albert D.Friesen 7/1/2019 6/10/1998
President, Chief Operating Officer NeilOwens 6/1/2022 7/1/2019
Chief Financial Officer HaarisUddin 6/1/2022 6/1/2022
4 additional Officers and Directors records available in full report.

Business Names
Business Name
Apigen Investments Limited
Apigen Investments Limited
Marley Drug, Inc.
10 additional Business Names available in full report.

General Information
Number of Employees: 25 (As of 12/31/2023)
Outstanding Shares: 10,436,313 (As of 6/30/2024)
Shareholders: 482
Stock Exchange: CVE
Fax Number: (204) 487-7412


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024